Long-term follow-up of novel post-transplant cyclophosphamide (PTCy) and abatacept (aba) graft-versus-host disease (GVHD) prophylaxis regimen compared to tacrolimus and methotrexate.
Kaitlyn C. Dykes(University of California San Diego), Dimitrios Tzachanis(Dana-Farber Cancer Institute), James K. Mangan(UC San Diego Health System), Ah‐Reum Jeong(University of California San Diego), Caitlin Costello(University of California San Diego), Aaron M. Goodman(University of California San Diego), Edward D. Ball(Sheba Medical Center), Tiffany Tanaka(UC San Diego Health System), Ayad Hamdan(University of California San Diego), Divya Koura(University of California San Diego)
Cited by 0
Related Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
|Nature Reviews Clinical Oncology|2016|464